Warfarin
Rivaroxaban a ‘viable alternative’ to warfarin for blood clots after heart attack
CHICAGO — In the RIVAWAR trial, patients hospitalized for a heart attack who were treated with rivaroxaban for left ventricular thrombus had comparable outcomes at 3 months to patients treated with warfarin.
Preventing first thrombosis remains top unmet need in antiphospholipid syndrome
SAN DIEGO — Preventing the first thrombosis, and better circumvention of the second, are currently the biggest obstacles in managing antiphospholipid syndrome, according to a speaker at the 2024 Congress of Clinical Rheumatology West.
DOACs reduce risk for dementia in AF vs. warfarin, especially in Asian patients
Compared with warfarin, direct oral anticoagulants were associated with reduced risk for dementia in patients with atrial fibrillation, particularly those from Asian populations, according to a systematic review and meta-analysis.
Study: Rivaroxaban shows similar safety, effectiveness to warfarin for patients with CKD
Rivaroxaban showed similar or lower risk for death, ischemic stroke and transient ischemic attack, and similar risk for bleeding compared with warfarin in adults with atrial fibrillation, according to recently published data.
DOACs for stroke prevention safe in most high-risk populations with AF
PHILADELPHIA — Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation are safe in most high-risk populations, a speaker said during the Heart in Diabetes CME Conference.
Apixaban may be superior vs. other anticoagulants for older patients with AF, dementia
Among older patients with atrial fibrillation and dementia, apixaban was associated with lower risk for stroke and major bleeding vs. dabigatran, rivaroxaban or warfarin, researchers reported.
No differences in bleeding, thromboembolic events with DOACs vs. warfarin after surgery
Patients who received apixaban or rivaroxaban after cardiac surgery were no more likely to experience major bleeding or thromboembolic events compared with patients who received warfarin after surgery, data from a single-center study show.
Reduced aspirin use linked to lower bleeding risk among patients on warfarin
An aspirin de-implementation intervention appeared associated with reduced bleeding risk patients hospitalized with atrial fibrillation and/or venous thromboembolism and taking warfarin, according to data published in JAMA Network Open.
Factor Xa inhibitor use linked to risk for ILD in patients with atrial fibrillation
In patients with nonvalvular atrial fibrillation receiving oral anticoagulants, factor Xa inhibitors appeared associated with increased risk for interstitial lung disease, according to a study published in JAMA Network Open.
INVICTUS
Vitamin K antagonist vs. rivaroxaban (Xarelto, Janssen/Bayer) for reducing rate of ischemic stroke and mortality in adults with rheumatic heart disease-associated atrial fibrillation.